Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Molalign Tarekegn Minwagaw, Betelihem Belete Akenie, Desalew Salew Tewabe, Awoke Seyoum Tegegne & Tariku Belachew Beyene. (2021) Predictors of Poor Adherence to CART and Treatment Failure at Second-Line Regimens Among Adults in Public Hospitals of Amhara Region, North-Western Ethiopia: A Retrospective Cohort Study. Patient Preference and Adherence 15, pages 2855-2864.
Read now
Read now
Vicente Soriano, Pablo Labarga, José V. Fernandez-Montero, Carmen de Mendoza, Laura Benítez-Gutiérrez, José M. Peña & Pablo Barreiro. (2017) Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opinion on Drug Metabolism & Toxicology 13:8, pages 807-816.
Read now
Read now
Isabella Esposito, Pablo Labarga, Pablo Barreiro, José V Fernandez-Montero, Carmen de Mendoza, Laura Benítez-Gutiérrez, José M Peña & Vicente Soriano. (2015) Dual antiviral therapy for HIV and hepatitis C – drug interactions and side effects. Expert Opinion on Drug Safety 14:9, pages 1421-1434.
Read now
Read now
Articles from other publishers (26)
Charlotte O’Halloran, Yvonne Gilleece, Suki Leung, Veronica Canuto, Connor McAlpine, Sophie Ross, Claire Norcross, Stuart Gaffney, Nipur Siani, William Hickey, Adam Moore, Olivera Rajkovic-Hooley & Ana Milinkovic. (2023) Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL). International Journal of STD & AIDS.
Crossref
Crossref
Zhao Wang, Prem Prakash Sharma, Brijesh Rathi, Minghui Xie, Erik De Clercq, Christophe Pannecouque, Dongwei Kang, Peng Zhan & Xinyong Liu. (2023)
Escaping from Flatland: Multiparameter Optimization Leads to the Discovery of Novel Tetrahydropyrido[4,3-
d
]pyrimidine Derivatives as Human Immunodeficiency Virus-1 Non-nucleoside Reverse Transcriptase Inhibitors with Superior Antiviral Activities against Non-nucleoside Reverse Transcriptase Inhibitor-Resistant Variants and Favorable Drug-like Profiles
. Journal of Medicinal Chemistry 66:13, pages 8643-8665.
Crossref
Crossref
Davide F. Bavaro, Andrea De Vito, Giuseppe Pasculli, Yagai Bouba, Laura Magnasco, Rachele Pincino, Francesco Saladini, Rossana Lattanzio, Romina Corsini, Serena Arima, Maurizio Zazzi, Francesca Incardona, Barbara Rossetti, Antonia Bezenchek, Borghi Vanni & Antonio Di Biagio. (2022) Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study. Journal of Medical Virology 94:8, pages 3890-3899.
Crossref
Crossref
Thomas Straubinger, Katherine Kay & Robert Bies. (2020) Modeling HIV Pre-Exposure Prophylaxis. Frontiers in Pharmacology 10.
Crossref
Crossref
Carey Hwang, Ming-Tain Lai & Daria Hazuda. (2019) Rational Design of Doravirine: From Bench to Patients. ACS Infectious Diseases 6:1, pages 64-73.
Crossref
Crossref
Ross D. CranstonCharlene S. DezzuttiAaron SiegelJarret EngstromCory ShetlerNicola Richardson-HarmanKaleab Z. AbebeDavid BackLaura ElseDeidre EganSaye KhooJames E. EganRonald StallPeter WilliamsRhonda M. BrandUrvi M. ParikhIan McGowan. (2019) A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. AIDS Research and Human Retroviruses 35:9, pages 794-804.
Crossref
Crossref
Vigneshwaran Namasivayam, Murugesan Vanangamudi, Victor G. Kramer, Sonali Kurup, Peng Zhan, Xinyong Liu, Jacob Kongsted & Siddappa N. Byrareddy. (2018) The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic. Journal of Medicinal Chemistry 62:10, pages 4851-4883.
Crossref
Crossref
Gaetana Sterrantino, Vanni Borghi, Anna Paola Callegaro, Bianca Bruzzone, Francesco Saladini, Franco Maggiolo, Gaetano Maffongelli, Massimo Andreoni, Michele De Gennaro, Nicola Gianotti, Patrizia Bagnarelli, Alessandra Vergori, Andrea Antinori, Maurizio Zazzi & Mauro Zaccarelli. (2019) Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. International Journal of Antimicrobial Agents 53:4, pages 515-519.
Crossref
Crossref
Jorge Soares, António Ferreira, André Silva-Pinto, Francisco Almeida, Carmela Piñeiro, Rosário Serrão & António Sarmento. (2019) The Influence of Antiretroviral Therapy on Hepatitis C Virus Viral Load and Liver Fibrosis in Human Immunodeficiency Virus-Coinfected Patients: An Observational Study. Intervirology 62:5-6, pages 182-190.
Crossref
Crossref
Francesca Ferretti & Marta Boffito. (2018) Rilpivirine long-acting for the prevention and treatment of HIV infection. Current Opinion in HIV and AIDS 13:4, pages 300-307.
Crossref
Crossref
Jean-Michel Molina, Kathleen Squires, Paul E Sax, Pedro Cahn, Johan Lombaard, Edwin DeJesus, Ming-Tain Lai, Xia Xu, Anthony Rodgers, Lisa Lupinacci, Sushma Kumar, Peter Sklar, Bach-Yen Nguyen, George J Hanna, Carey Hwang, Marcelo Martins, Pedro Enrique Cahn, Gustavo D. Lopardo, Norma Porteiro, Mark Theo Bloch, David Alfred Baker, Norman Roth, Richard James Moore, Robert James Finlayson, James McMahon, Armin Rieger, Alexander Zoufaly, Sylvia Hartl, Robert Zangerle, Fiona Smaill, Sharon L. Walmsley, Brian Conway, Anita Rachlis, Graham H.R. Smith, Carlos Perez, Alejandro Afani, Maria Isabel E. Campos Barker, Carolina Eugenia Chahin, Marcelo Wolff Reyes, Jan Gerstoft, Nina Weis, Alex Lund Laursen, Jean-Michel Molina, Yazdan Yazdanpanah, Laurent Cotte, Francois Raffi, Philippe Morlat, Pierre-Marie Girard, Christine Katlama, Juergen K. Rockstroh, Keikawus Arasteh, Stefan Esser, Albrecht Stoehr, Hans-Juergen Stellbrink, Matthias Stoll, Dirk Schuermann, Gerd Faetkenheuer, Johannes Bogner, Thomas Lutz, Axel Baumgarten, Hans Jaeger, Andrea Gori, Gabriel Coltan, Felicia Constandis, Simona Manuela Erscoiu, Liviu-Jany Prisacariu, Sorin Rugina, Adrian Streinu-Cercel, Vadim Valentinovich Pokrovsky, Natalia V. Zakharova, Andrey Anatolyevich Shuldyakov, Elena Pavlovna Ryamova, Valeriy Viktorovich Kulagin, Olga Aleksandrovna Tsybakova, Elena Orlova-Morozova, Firaya Nagimova, Evgeniy Voronin, Tatyana Evgenyevna Shimonova, Oleg Anatolyevich Kozyrev, Catherine Orrell, Johannes Jurgens Lombaard, Margaretha Elizabeth Botes, Joaquin Portilla, Josep Maria Gatell, Maria Jesus Perez, Jose Ramon Arribas, Eugenia Negredo, Daniel Podzamczer, Federico Pulido, Jesus Troya, Ignacio De los Santos, Juan Berenguer, Ian G. Williams, Margaret A. Johnson, Gabriel Schembri, Amanda Clarke, Mark Gompels, Julie Meriel Fox, Steven John Taylor, Stephen Kegg, Debbie P. Hagins, Olayemi O. Osiyemi, David James Prelutsky, Moti N. Ramgopal, Robin Dretler, Edwin DeJesus, Louis Sloan, Stanley T. Lewis, Patrick G. Clay, Nicholaos C. Bellos, Melanie A. Thompson, Jose Montero, Cheryl K. McDonald, Catherine Creticos, David Shamblaw, Antonio E. Terrelonge, Martin Valdes, Karen T. Tashima, William J. Robbins, Franco Antonio Felizarta, Richard A. Elion, Jihad Slim, Jacob Paul Lalezari, Sujata N. Lalla-Reddy, Peter Jerome Ruane, Anthony Mills, Jerry L. Cade, Rafael E. Campo, Craig A. Dietz, Gary Blick, Cynthia Mayer, Juan Carlos Rondon, Paul P. Cook, Eric Daar, Princy N. Kumar, Susan Swindells, Jose Guillermo Castro, Javier O. Morales-Ramirez, Lizette Santiago & Jorge L. Santana-Bagur. (2018) Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. The Lancet HIV 5:5, pages e211-e220.
Crossref
Crossref
V. T. Valuev-Elliston & S. N. Kochetkov. (2018) Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: A combinatorial approach. Biochemistry (Moscow) 82:13, pages 1716-1743.
Crossref
Crossref
Lei Wei, Hui-Ling Wang, Li Huang, Chin-Ho Chen, Susan L. Morris-Natschke, Kuo-Hsiung Lee & Lan Xie. (2017) Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus. Bioorganic & Medicinal Chemistry Letters 27:12, pages 2788-2792.
Crossref
Crossref
Ian McGowan, Charlene S Dezzutti, Aaron Siegel, Jarret Engstrom, Alexiy Nikiforov, Kathryn Duffill, Cory Shetler, Nicola Richardson-Harman, Kaleab Abebe, David Back, Laura Else, Deidre Egan, Saye Khoo, James E Egan, Ronald Stall, Peter E Williams, Khaleel K Rehman, Amy Adler, Rhonda M Brand, Beatrice Chen, Sharon Achilles & Ross D Cranston. (2016) Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. The Lancet HIV 3:12, pages e569-e578.
Crossref
Crossref
Wenmin Chen, Peng Zhan, Dirk Daelemans, Jiapei Yang, Boshi Huang, Erik De Clercq, Christophe Pannecouque & Xinyong Liu. (2016) Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. European Journal of Medicinal Chemistry 121, pages 352-363.
Crossref
Crossref
Alejandro Sosnik. (2016) Drug self-assembly: A phenomenon at the nanometer scale with major impact in the structure–biological properties relationship and the treatment of disease. Progress in Materials Science 82, pages 39-82.
Crossref
Crossref
Vincent Calvez, Anne-Genevieve Marcelin, Johan Vingerhoets, Andrew Hill, Blanca Hadacek & Christiane Moecklinghoff. (2015) Systematic Review to Determine the Prevalence of Transmitted Drug Resistance Mutations to Rilpivirine in HIV-Infected Treatment-Naive Persons. Antiviral Therapy 21:5, pages 405-412.
Crossref
Crossref
Anna H. Tran, Brookie M. Best, Alice Stek, Jiajia Wang, Edmund V. Capparelli, Sandra K. Burchett, Regis Kreitchmann, Kittipong Rungruengthanakit, Kathleen George, Tim R. Cressey, Nahida Chakhtoura, Elizabeth Smith, David E. Shapiro & Mark Mirochnick. (2016) Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. JAIDS Journal of Acquired Immune Deficiency Syndromes 72:3, pages 289-296.
Crossref
Crossref
Valeria Cozzi, Nitin Charbe, Sara Baldelli, Simone Castoldi, Chiara Atzori, Dario Cattaneo & Emilio Clementi. (2016) Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma. Therapeutic Drug Monitoring 38:3, pages 407-413.
Crossref
Crossref
Kevin K. Ariën, Muthusamy Venkatraj, Johan Michiels, Jurgen Joossens, Katleen Vereecken, Pieter Van der Veken, Jan Heeres, Hans De Winter, Leo Heyndrickx, Koen Augustyns & Guido Vanham. (2016) Resistance and cross-resistance profile of the diaryltriazine NNRTI and candidate microbicide UAMC01398. Journal of Antimicrobial Chemotherapy 71:5, pages 1159-1168.
Crossref
Crossref
Na Liu, Lei Wei, Li Huang, Fei Yu, Weifan Zheng, Bingjie Qin, Dong-Qin Zhu, Susan L. Morris-Natschke, Shibo Jiang, Chin-Ho Chen, Kuo-Hsiung Lee & Lan Xie. (2016) Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. Journal of Medicinal Chemistry 59:8, pages 3689-3704.
Crossref
Crossref
Dirk Schürmann, Christian Sobotha, Jocelyn Gilmartin, Martine Robberechts, Inge De Lepeleire, Ka Lai Yee, Ying Guo, Rachael Liu, Frank Wagner, John A. Wagner, Joan R. Butterton & Matt S. Anderson. (2016) A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals. AIDS 30:1, pages 57-63.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
687
736
.
Ian McGowan. (2015) Injectable and implantable antiretroviral strategies for HIV prevention. Future Virology 10:10, pages 1163-1176.
Crossref
Crossref
Martin Markowitz & Kathrine Meyers. (2015) Extending access with long-acting antiretroviral therapy. Current Opinion in HIV and AIDS 10:4, pages 216-218.
Crossref
Crossref
Akil Jackson & Ian McGowan. (2015) Long-acting rilpivirine for HIV prevention. Current Opinion in HIV and AIDS 10:4, pages 253-257.
Crossref
Crossref